Thanks, Anon. -- I Was Remiss, In Not Getting To This: Merck/NewLink Ebola Vaccine, Now With TWO Years' Durability Data...

I admit that I've had quite a bit "in the real world" on my plate -- of late. Even so, that is no excuse: I am decidedly tardy in mentioning Merck's very nice first line lung cancer data, and in mentioning the below -- also very good news.

Thanks go to the faithful Anon. commenter who reminded me of the Lancet release having cleared embargo. More broadly, it is very encouraging to know that the Merck vaccine is showing a durable sero-positivity, in the wild (so to speak).

Let us hope that we see similar data three and five years on, as well. In any event, here is FierceVaccines on it all -- and a bit:

. . . .The new study, published in Lancet Infectious Diseases, shows antibodies persist for two years after a single shot of Merck’s rVSV-ZEBOV vaccine.

Researchers examined participants from a previous phase 1 study who returned for follow-up research. All 44 of those patients who had received a high dose of the vaccine remained seropositive at two years, and 33 of 37 who got a lower dose were still seropositive. . . .

Now you know. With my eldest in Paris and Provence for ten days, and launching a new travel magazine, I am sorely tempted (coldest April here, in over 130 years!) to hop a plane -- and go missing for a few, as early next week. We shall see -- as I could catch No. 2 in London, same trip, for Indian food!

Today is chilly, but quite clear, so I may just stay put. Dunno. . . . Onward, now to lunch -- with Riot Blockchain swooning (again, the former BiOptix) -- it's good for my personal predictive portfolio, anew. . . . grin.

नमस्ते